Effect of iodothyronine hormone status on doxorubicin related cardiotoxicity

• Autorzy: Dudka J. , Mandziuk S. , Madej-Czerwonka B. , Sierocinska-Sawa J. , Walczyna B. , Korga A. , Cendrowska-Pinkosz M. , Burdan F.
• Języki publikacji: EN

Abstrakty

EN

The anthracycline anticancer agent doxorubicin has been recognised to induce a dose-dependent cardiotoxicity. The chronic form of such complication is characterised by an irreversible cardiac damage and congestive heart failure. Although the pathogenesis of anthracycline cardiotoxicity seems to be multifactorial, the pivotal role has been attributed to reactive oxygen species formation. Because redox equilibrium in cardiomyocytes may be regulated via iodothyronine hormones, the aim of the study was to appraise the effect of hypothyroidism on heart damages induced by doxorubicin. The rats received methimazole in drinking water (0.001 and 0.025%) after doxorubicin administration (2.0, 5.0 and 15 mg/kg). The cardiac morphology and blood biochemical markers of heart damage were assessed. Decreased levels of iodothyronine hormones had not significant impact on cardiac morphological changes and no effect on the level of B-type natriuretic peptide in rats receiving doxorubicin. Lower hormonal levels had sporadic, diverse effect on blood transaminases, lactate dehydrogenase and creatine kinase levels, but any relation to time, doxorubicin doses and hypothyroid status was found. Hypothyreosis leads to increase in fatty acid binding protein in rats receiving higher dose of doxorubicin. Hypothyreosis had no effect on heart stretching and on necrosis at morphological level, but caused biochemical symptoms of cardiomyocyte necrosis in rats receiving doxorubicin. (Folia Morphol 2013; 72, 4: 340–348)

Słowa kluczowe

EN

iodothyronine hormone; doxorubicin; cardiotoxicity; hypothyreosis; anticancer agent

• Wydawca: -
• Czasopismo: Folia Morphologica
• Rocznik: 2013
• Tom: 72
• Numer: 4
• Opis fizyczny: p.340-348,fig.,ref.

Twórcy

autor

Dudka J.

• Medical Biology Unit, Medical University of Lublin, Jaczewskiego 8, 20-090 Lublin, Poland

autor

Mandziuk S.

• Department of Pneumology Oncology and Alergology, Medical University of Lublin, Lublin, Poland

autor

Madej-Czerwonka B.

• Department of Human Anatomy, Medical University of Lublin, Lublin, Poland

autor

Sierocinska-Sawa J.

• Department of Clinical Pathomorphology, Medical University of Lublin, Lublin, Poland

autor

Walczyna B.

• Department of Clinical Pathomorphology, Medical University of Lublin, Lublin, Poland

autor

Korga A.

• Medical Biology Unit, Medical University of Lublin, Jaczewskiego 8, 20-090 Lublin, Poland

autor

Cendrowska-Pinkosz M.

• Department of Human Anatomy, Medical University of Lublin, Lublin, Poland

autor

Burdan F.

• Department of Human Anatomy, Medical University of Lublin, Lublin, Poland
• St.John’s Cancer Centre, Lublin, Poland

Bibliografia

• 1. Abalovich M, Llesuy S, Gutierrez S, Repetto M (2003) Peripheral parameters of oxidative stress in Graves’ disease: the effects of methimazole and 131 iodine treatments. Clin Endocrinol, 59: 321–327.
• 2. Abd El-Gawad HM, El-Sawalhi MM (2004) Nitric oxide and oxidative stress in brain and heart of normal rats treated with doxorubicin: role of aminoguanidine. J Biochem Mol Toxicol, 18: 69–77.
• 3. Al-Shabanah O (1998) Captopril ameliorates myocardial and hematological toxicities induced by adriamycin. Biochem Mol Biol Int, 45: 419–427.
• 4. Andican G, Gelişgen R, Civelek S, Seven A, Seymen O, Altuğ T, Yiğit G, Burçak G (2004) Oxidative damage to nuclear DNA in hyperthyroid rat liver: inability of vitamin C to prevent the damage. J Toxicol Environ Health A, 67: 413–420.
• 5. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM (2000) Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res, 60: 1789–1792.
• 6. Büyükokuroğlu ME, Taysi S, Buyukavci M, Bakan E (2004) Prevention of acute adriamycin cardiotoxicity by dantrolene in rats. Hum Exp Toxicol, 23: 251–256.
• 7. Chattopadhyay S, Zaidi G, Das K, Chainy GB (2003) Effects of hypothyroidism induced by 6-n-propylthiouracil and its reversal by T3 on rat heart superoxide dismutase, catalase and lipid peroxidation. Indian J Exp Biol, 41: 846–849.
• 8. Chen GF, Ronis MJ, Ingelman-Sundberg M, Badger TM (1999) Hormonal regulation of microsomal cytochrome P4502E1 and P450 reductase in rat liver and kidney. Xenobiotica, 29, 437–451.
• 9. Deepa PR, Varalakshmi P (2003) Protective effect of low molecular weight heparin on oxidative injury and cellular abnormalities in adriamycin-induced cardiac and hepatic toxicity. Chem Biol Interact, 146: 201–210.
• 10. Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ (2001) Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest, 108: 585–590.
• 11. Dudka J, Burdan F, Korga A, Dyndor K, Syroka I, Zieba J, Lewkowicz D, Korobowicz-Markiewicz A (2009) The diagnosis of anthracycline-induced cardiac damage and heart failure. Postepy Hig Med Dosw, 63: 225–233.
• 12. Dudka J, Burdan F, Korga A, Iwan M, Madej-Czerwonka B, Cendrowska-Pinkosz M, Korobowicz-Markiewicz A, Jodlowska-Jedrych B, Matysiak W (2012) Intensification of doxorubicin-related oxidative stress in the heart by hypothyroidism is not related to the expression of cytochrome P450 NADPH-reductase and inducible nitric oxide synthase, as well as activity of xanthine oxidase. Oxid Med Cell Longev, 2012: 139327.
• 13. Dudka J (2006) The role of reactive oxygen and nitrogen species in calcium and iron homeostasis dysregulation in anthracycline cardiotoxicity. Postepy Hig Med Dosw, 60: 241–247.
• 14. Dziegiel P, Surowiak P, Zabel M (2002) Correlation of histopathological and biochemical appraisal of anthracyclin-induced myocardium damage. Folia Histochem Cytobiol, 40: 127–128.
• 15. Flores-Morales A, Gullberg H, Fernandez L, Ståhlberg N, Lee NH, Vennström B, Norstedt G (2002) Patterns of liver gene expression governed by TRbeta. Mol Endocrinol, 16: 1257–1268.
• 16. Komosinska-Vassev K, Olczyk K, Kucharz EJ, Marcisz C, Winsz-Szczotka K, Kotulska A (2000) Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves’ disease during therapy. Clin Chim Acta, 300: 107–117.
• 17. Liu D, Waxman DJ (2002) Post-transcriptional regulation of hepatic NADPH-cytochrome P450 reductase by thyroid hormone: independent effects on poly(A) tail length and mRNA stability. Mol Pharmacol, 61: 1089–1096.
• 18. Liu X, Chen Z, Chua CC, Ma YS, Youngberg GA, Hamdy R, Chua BH (2002) Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol, 283: H254–H263.
• 19. Lombardi A, Beneduce L, Moreno M, Diano S, Colantuoni V, Ursini MV, Lanni A, Goglia F (2000) 3,5-diiodo-L-thyronine regulates glucose-6-phosphate dehydrogenase activity in the rat. Endocrinology, 141: 1729–1734.
• 20. Mayer L, Romić Z, Skreb F, Bacić-Vrca V, Cepelak I, Zanić-Grubisić T, Kirin M (2004) Antioxidants in patients with hyperthyroidism. Clin Chem Lab Med, 42: 154–158.
• 21. Minotti G, Recalcati S, Menna P, Salvatorelli E, Corna G, Cairo G (2004) Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms. Methods Enzymol, 378: 340–361.
• 22. O’Brien PJ, Smith DE, Knechtel TJ, Marchak MA, Pruimboom-Brees I, Brees DJ, Spratt DP, Archer FJ, Butler P, Potter AN, Provost JP, Richard J, Snyder PA, Reagan WJ (2006) Cardiac troponin I is a sensitive, specific biomarker of cardiac injury in laboratory animals. Lab Anim, 40: 153–171.
• 23. Ohkaru Y, Asayama K, Ishii H, Nishimura S, Sunahara N, Tanaka T, Kawamura K (1995) Development of a sandwich enzyme-linked immunosorbent assay for the determination of human heart type fatty acid-binding protein in plasma and urine by using two different monoclonal antibodies specific for human heart fatty acid-binding protein. J Immunol Methods, 178: 99–111.
• 24. Pelsers MM, Chapelle JP, Knapen M, Vermeer C, Muijtjens AM, Hermens WT, Glatz JF (1999) Influence of age and sex and day-to-day and within-day biological variation on plasma concentrations of fatty acid-binding protein and myoglobin in healthy subjects. Clin Chem, 45: 441–443.
• 25. Ram PA, Waxman DJ (1992) Thyroid hormone stimulation of NADPH P450 reductase expression in liver and extrahepatic tissues. Regulation by multiple mechanisms. J Biol Chem, 267, 3294–3301.
• 26. Sadowski T (2002) Biochemiczne markery zawału mięśnia sercowego. LabForum, http://www.rochediagnostics.pl/content/archiwum/labforum/pdf/labforum13.pdf.
• 27. Szczeklik A (2012) Interna Szczeklika 2012. Podręcznik chorób wewnętrznych (in Polish). Medycyna Praktyczna, Krakow.
• 28. Waxman DJ, Morrissey JJ, Leblanc GA (1989) Hypophysectomy differentially alters P-450 protein levels and enzyme activities in rat liver: pituitary control of hepatic NADPH cytochrome P-450 reductase. Mol Pharmacol, 35: 519–525.
• 29. Yagmurca M, Fadillioglu E, Erdogan H, Ucar M, Sogut S, Irmak MK (2003) Erdosteine prevents doxorubicin-induced cardiotoxicity in rats. Pharmacol Res, 48: 377–382.